Vant

Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors

Retrieved on: 
Monday, April 29, 2024
Amazon (company), AstraZeneca, Public sector, University, AMZN, SAP SuccessFactors, AI, Climate, Fintech, Chairperson, Express Scripts, Genentech, Vant, Trustee, XYZ, Growth, Roivant Sciences, Engineering, DNA, Helmy Eltoukhy, Plumtree Software, Liberty Mutual, Bristol Myers Squibb, University of Chicago, Biology, Symantec, Merck, Biotechnology, Management

And I could not be more grateful to Marijn and Reshma for their leadership and guidance over this truly evolutionary period for Ginkgo.

Key Points: 
  • And I could not be more grateful to Marijn and Reshma for their leadership and guidance over this truly evolutionary period for Ginkgo.
  • Myrtle Potter brings over 25 years of experience leading and advising global technology and life sciences companies and serving on public company boards.
  • Until recently, Ms. Potter served as President, Chief Executive Officer, and Chair of the board of Sumitomo Pharma America.
  • Ross Fubini founded XYZ Venture Capital, a venture capital investment firm, in 2017, and serves as Managing Director.

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Retrieved on: 
Monday, October 23, 2023
Bispecific monoclonal antibody, Hart–Scott–Rodino Antitrust Improvements Act, ROG, RO, Fibrosis, Maintenance, Inflammation, Wardwell, Ulcerative colitis, Inflammatory bowel disease, Vant, Partnership, Webcast, TL1A, M.D, Patient, Citigroup, Pharmaceutical industry, Fine chemical, Roivant Sciences, Pfizer

The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody.

Key Points: 
  • The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody.
  • RVT-3101 is a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
  • The global, randomized, double-blinded, placebo controlled trial delivered the first long-term, dose finding data in a large number of patients (n=245).
  • Telavant was jointly formed by Roivant and Pfizer in 2022 to develop and commercialize RVT-3101 in the US and Japan.

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

Retrieved on: 
Thursday, July 27, 2023
CD, Therapy, Inflammatory Bowel Diseases, IBD, Disease, Amsterdam, Inflammation, Fibrosis, Vant, Patient, CDAI, Safety, Pharmaceutical industry, UC, Roivant Sciences

The TAHOE study ( NCT05910528 ) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease.

Key Points: 
  • The TAHOE study ( NCT05910528 ) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease.
  • The primary and key secondary endpoints are the proportion of participants achieving clinical remission by Crohn's Disease Activity Index (CDAI) and the proportion of participants achieving endoscopic response at week 14.
  • This was the first-ever long-duration data reported for an anti-TL1A antibody.
  • Across all doses and patient groups, RVT-3101 was well tolerated and showed a favorable safety profile.

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Environment, Science, PFE, Risk, Fibroblast, Safety, Patient, Maintenance, TL1A, Inflammation, Gastrointestinal tract, NYSE, Ulcerative colitis, Inflammatory Bowel Diseases, Research, Development, TH1, Fibrosis, UC, Inflammatory bowel disease, News, Clinical trial, Vaccine, Fine chemical, Pharmaceutical industry, Audit, Vant, Roivant Sciences, Pfizer

The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1.

Key Points: 
  • The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1.
  • As such, RVT-3101 has the potential to provide greater efficacy by hitting multiple inflammatory pathways as well as fibrotic pathways.
  • We are excited about this collaboration with Pfizer on a potential first-in-class program, which we intend to pursue in both ulcerative colitis and in additional inflammatory and fibrotic diseases.
  • It is estimated that up to 2 million US adults suffer from inflammatory bowel diseases, which include ulcerative colitis and Crohns disease.

Guardant Health Appoints Myrtle Potter to Its Board of Directors

Retrieved on: 
Wednesday, October 20, 2021
Health, Oncology, Medical Devices, Liberty Mutual, University, University of Chicago, Cancer, Knowledge, Industry, Amazon (company), Merck, Bristol Myers Squibb, Patient, Helmy Eltoukhy, Trustee, Bachelor, Vant, Commercial Operating System (COS), LLC, Company, Board, Health, Medco Health Solutions, Roivant Sciences, Therapy, AstraZeneca, GH, Board of directors, Pharmaceutical industry

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.
  • We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on our mission of conquering cancer with data, said Helmy Eltoukhy, Guardant Health Co-CEO and Chairman of the Board.
  • I am thrilled to be joining Guardant Healths Board of Directors at such a significant time for the company, said Myrtle Potter.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center

Retrieved on: 
Monday, November 26, 2018
Vant, Cincinnati, Pharma

The launch of Aruvant builds on a partnership between Roivant and Innovation Ventures, the commercialization arm of Cincinnati Children's, dating back to early 2015.

Key Points: 
  • The launch of Aruvant builds on a partnership between Roivant and Innovation Ventures, the commercialization arm of Cincinnati Children's, dating back to early 2015.
  • Myrtle Potter, Vant Operating Chair at Roivant Pharma, will serve as Chairman of Aruvant.
  • RVT-1801 was developed in the laboratory of Dr. Punam Malik, Director of the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children's.
  • Roivant Pharma companies include Axovant, Myovant, Dermavant, Enzyvant, Urovant, Metavant, Genevant, Altavant, Immunovant, Respivant, Aruvant, and Arbutus.